for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

メルク・アンド・カンパニー・インク

MRK.N

現在値

91.41USD

変化

0.37(+0.41%)

出来高

785,338

本日のレンジ

90.53

 - 

91.83

52週レンジ

70.90

 - 

95.72

∙ 約20分前の相場を表示しています。

適時開示

FDA Grants Priority Review for Supplemental NDA For Lynparza® With Abiraterone And Prednisone Or Prednisolone For Prostate Cancer

Aug 16 (Reuters) - Merck & Co Inc <MRK.N>::FDA ACCEPTS SUBMISSION OF SUPPLEMENTAL NEW DRUG APPLICATION FOR LYNPARZA® (OLAPARIB) IN COMBINATION WITH ABIRATERONE AND PREDNISONE OR PREDNISOLONE FOR PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND GRANTS PRIORITY REVIEW.FDA ACCEPTS SUBMISSION OF SUPPLEMENTAL NEW DRUG APPLICATION FOR LYNPARZA® (OLAPARIB) IN COMBINATION WITH ABIRATERONE AND PREDNISONE OR PREDNISOLONE FOR PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND GRANTS PRIORITY REVIEW.MERCK & CO INC - FDA HAS SET A PRESCRIPTION DRUG USER FEE ACT (PDUFA), OR TARGET ACTION, DATE IN Q4 OF 2022.

Merck And Orna Therapeutics Collaborate To Advance Orna's Next Generation Of RNA Technology

Aug 16 (Reuters) - Merck & Co Inc <MRK.N>::MERCK AND ORNA THERAPEUTICS COLLABORATE TO ADVANCE ORNA’S NEXT GENERATION OF RNA TECHNOLOGY.MERCK & CO INC - UNDER TERMS OF AGREEMENT, MERCK WILL MAKE AN UPFRONT PAYMENT TO ORNA OF $150 MILLION.MERCK & CO INC - ORNA WILL BE ELIGIBLE TO RECEIVE UP TO $3.5 BILLION IN DEVELOPMENT, REGULATORY, AND SALES MILESTONES.MERCK & CO INC - UPFRONT PAYMENT TO ORNA OF $150 MILLION WILL BE EXPENSED BY MERCK IN Q3 OF 2022 AND INCLUDED IN NON-GAAP RESULTS.MERCK & CO INC - WILL ALSO INVEST $100 MILLION OF EQUITY IN ORNA'S RECENTLY COMPLETED SERIES B FINANCING ROUND.MERCK & CO INC - ORNA WILL RETAIN RIGHTS TO ITS ORNA-LNP TECHNOLOGY PLATFORM.

Merck And Eisai Provide Update On Phase 3 LEAP-002 Trial Evaluating Keytruda® (Pembrolizumab) Plus LENVIMA® (Lenvatinib) Versus LENVIMA Monotherapy In Patients With Unresectable Hepatocellular C

Aug 3 (Reuters) - Merck & Co Inc <MRK.N>::MERCK AND EISAI PROVIDE UPDATE ON PHASE 3 LEAP-002 TRIAL EVALUATING KEYTRUDA® (PEMBROLIZUMAB) PLUS LENVIMA® (LENVATINIB) VERSUS LENVIMA MONOTHERAPY IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA.MERCK - PROPOSED DEAL FOR THERE WERE TRENDS TOWARD IMPROVEMENT IN OS AND PFS FOR PATIENTS WHO RECEIVED KEYTRUDA PLUS LENVIMA VERSUS LENVIMA MONOTHERAPY.MERCK & CO INC - MONOTHERAPY DID NOT MEET ITS DUAL PRIMARY ENDPOINTS OF OVERALL SURVIVAL (OS) AND PROGRESSION-FREE SURVIVAL (PFS).MERCK & CO INC - RESULTS DID NOT MEET STATISTICAL SIGNIFICANCE PER PRE-SPECIFIED STATISTICAL PLAN.MERCK & CO INC - SAFETY PROFILE OF KEYTRUDA PLUS LENVIMA WAS CONSISTENT WITH PREVIOUSLY REPORTED DATA ON COMBINATION.MERCK & CO INC - RESULTS FROM LEAP-002 TRIAL DO NOT AFFECT CURRENT APPROVED INDICATIONS FOR KEYTRUDA PLUS LENVIMA COMBINATION.MERCK & CO INC - WILL CONTINUE TO INVESTIGATE THE COMBINATION'S ROLE ACROSS MULTIPLE TYPES OF CANCER.

Merck Provides Update On Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA® (Pembrolizumab) Plus Chemotherapy In Patients With Metastatic Castration-Resistant Prostate Cancer

Aug 3 (Reuters) - Merck & Co Inc <MRK.N>::MERCK PROVIDES UPDATE ON PHASE 3 KEYNOTE-921 TRIAL EVALUATING KEYTRUDA® (PEMBROLIZUMAB) PLUS CHEMOTHERAPY IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER.MERCK & CO INC - RESULTS DID NOT MEET STATISTICAL SIGNIFICANCE PER PRE-SPECIFIED STATISTICAL PLAN.MERCK & CO INC- SAFETY PROFILE OF KEYTRUDA IN THIS TRIAL WAS CONSISTENT WITH THAT OBSERVED IN PREVIOUSLY REPORTED STUDIES.

Merck Reports Second-Quarter 2022 Worldwide Sales Of $14.6 Billion, Up 28%

July 28 (Reuters) - Merck & Co Inc <MRK.N>::MERCK - SECOND-QUARTER 2022 WORLDWIDE SALES WERE $14.6 BILLION, AN INCREASE OF 28%.MERCK - QTRLY KEYTRUDA SALES GREW 26% TO $5.3 BILLION; EXCLUDING IMPACT FROM FOREIGN EXCHANGE, SALES GREW 30%.MERCK - QTRLY GARDASIL/GARDASIL 9 SALES GREW 36% TO $1.7 BILLION; EXCLUDING IMPACT FROM FOREIGN EXCHANGE, SALES GREW 40%.MERCK - Q2 2022 GAAP EPS FROM CONTINUING OPERATIONS WAS $1.55; Q2 2022 NON-GAAP EPS WAS $1.87.MERCK - QTRLY JANUVIA / JANUMET SALES OF $1.23 BILLION, DOWN 2%.MERCK - CO RAISES & NARROWS EXPECTED FY 2022 WORLDWIDE SALES RANGE TO BE BETWEEN $57.5 BILLION AND $58.5 BILLION.MERCK - CO NARROWS EXPECTED FY 2022 NON-GAAP EPS RANGE TO BE BETWEEN $7.25 AND $7.35, INCLUDING NEGATIVE IMPACT FROM FOREIGN EXCHANGE OF ABOUT 3%.MERCK - CO EXPECTS FY 2022 GAAP EPS TO BE BETWEEN $5.89 AND $5.99.Further company coverage: MRK.N. ((Reuters.Briefs@thomsonreuters.com;)).

Pmv Pharmaceuticals Announces Clinical Trial Collaboration With Merck To Evaluate PC14586 In Combination With Keytruda In Patients With Advanced Solid Tumors

July 18 (Reuters) - PMV Pharmaceuticals Inc <PMVP.O>::PMV PHARMACEUTICALS ANNOUNCES A CLINICAL TRIAL COLLABORATION WITH MERCK TO EVALUATE PC14586 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH ADVANCED SOLID TUMORS.PMV PHARMACEUTICALS - ENTERED CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH MERCK TO EVALUATE PC14586 IN COMBINATION WITH MERCK'S KEYTRUDA.PMV PHARMACEUTICALS INC - WILL EVALUATE PC14586 IN COMBINATION WITH KEYTRUDA AS A SEPARATE ARM OF COMPANY'S ONGOING PHASE 1/2 PYNNACLE TRIAL.

Orion And MSD To Collaborate On ODM-208 For Treatment Of Metastatic Castration-Resistant Prostate Cancer

July 13 (Reuters) - Orion Oyj <ORNBV.HE>::ORION AND MSD ANNOUNCE GLOBAL COLLABORATION FOR THE DEVELOPMENT AND COMMERCIALISATION OF ODM-208, AN INVESTIGATIONAL STEROID SYNTHESIS INHIBITOR FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER.ORION TO RECEIVE AN UPFRONT PAYMENT OF USD 290 MILLION.CO AND MSD, ACTING VIA MERCK SHARP & DOHME LLC, WILL CO-DEVELOP AND CO-COMMERCIALISE ODM-208.WILL BE RESPONSIBLE FOR MANUFACTURE OF CLINICAL AND COMMERCIAL SUPPLY OF ODM-208.

Merck Is In Advanced Talks To Buy Seagen - WSJ

July 6 (Reuters) - :MERCK IS IN ADVANCED TALKS TO BUY SEAGEN - WSJ.COMPANIES ARE DISCUSSING A PRICE FOR SEAGEN ABOVE $200 A SHARE - WSJ.

Merck Pushes Forward With Potential Deal For Seagen - WSJ

June 23 (Reuters) - :MERCK PUSHES FORWARD WITH POTENTIAL DEAL FOR SEAGEN - WSJ.

FDA Approves Merck's Vaxneuvance For Invasive Pneumococcal Disease Prevention In Infants And Children

June 22 (Reuters) - Merck & Co Inc <MRK.N>::U.S. FDA APPROVES MERCK’S VAXNEUVANCE™ (PNEUMOCOCCAL 15-VALENT CONJUGATE VACCINE) FOR THE PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE IN INFANTS AND CHILDREN.MERCK & CO INC- U.S. CDC ACIP IS EXPECTED TO MEET TODAY TO DISCUSS AND MAKE RECOMMENDATIONS ON USE OF VAXNEUVANCE IN PEDIATRIC POPULATIONS.MERCK & CO INC- U.S. FDA HAS APPROVED AN EXPANDED INDICATION FOR VAXNEUVANCE TO INCLUDE CHILDREN 6 WEEKS THROUGH 17 YEARS OF AGE.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up